First Bancorp Inc ME Has $260,000 Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

First Bancorp Inc ME boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.3% during the 1st quarter, Holdings Channel reports. The institutional investor owned 1,970 shares of the medical equipment provider’s stock after purchasing an additional 100 shares during the quarter. First Bancorp Inc ME’s holdings in Zimmer Biomet were worth $260,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. OLD Point Trust & Financial Services N A bought a new stake in shares of Zimmer Biomet during the 4th quarter valued at $26,000. Ables Iannone Moore & Associates Inc. bought a new position in Zimmer Biomet during the 4th quarter worth about $30,000. Naples Money Management LLC bought a new position in Zimmer Biomet during the 4th quarter worth about $35,000. Activest Wealth Management increased its holdings in Zimmer Biomet by 410.4% during the 4th quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after purchasing an additional 275 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Zimmer Biomet by 48.4% during the 4th quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock worth $52,000 after buying an additional 153 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ZBH. Citigroup increased their price objective on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Oppenheimer lifted their price target on shares of Zimmer Biomet from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. The Goldman Sachs Group started coverage on shares of Zimmer Biomet in a research report on Thursday, May 30th. They issued a “neutral” rating and a $129.00 price target for the company. Truist Financial dropped their price target on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research report on Friday, May 3rd. Finally, Evercore ISI boosted their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet has an average rating of “Hold” and an average target price of $133.75.

Zimmer Biomet Stock Down 0.2 %

Shares of NYSE ZBH traded down $0.27 during trading on Wednesday, hitting $107.95. 1,339,724 shares of the company traded hands, compared to its average volume of 1,480,131. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $147.50. The firm has a market capitalization of $22.21 billion, a price-to-earnings ratio of 23.50, a P/E/G ratio of 1.95 and a beta of 1.02. The business’s fifty day moving average is $116.00 and its 200 day moving average is $121.42.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the business posted $1.89 EPS. The firm’s revenue was up 3.2% compared to the same quarter last year. Equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be paid a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.